

**USP39 Antibody (Center)**  
**Affinity Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP18677c**

**Specification**

---

**USP39 Antibody (Center) - Product Information**

Application	WB,E
Primary Accession	<a href="#">Q53GS9</a>
Other Accession	<a href="#">Q3TIX9</a> , <a href="#">NP_006581.2</a>
Reactivity	Human
Predicted	Mouse
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	65381
Antigen Region	237-265

**USP39 Antibody (Center) - Additional Information**

**Gene ID** 10713

**Other Names**

U4/U6U5 tri-snRNP-associated protein 2, Inactive ubiquitin-specific peptidase 39, SAD1 homolog, U4/U6U5 tri-snRNP-associated 65 kDa protein, 65K, USP39

**Target/Specificity**

This USP39 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 237-265 amino acids from the Central region of human USP39.

**Dilution**

WB~~1:1000

E~~Use at an assay dependent concentration.

**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

USP39 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

**USP39 Antibody (Center) - Protein Information**

**Name** USP39 ([HGNC:20071](#))

**Function** Deubiquitinating enzyme that plays a role in many cellular processes including cellular antiviral response, epithelial morphogenesis, DNA repair or B-cell development (PubMed:[33127822](#), PubMed:[34614178](#)). Plays a role in pre-mRNA splicing as a component of the U4/U6-U5 tri-snRNP, one of the building blocks of the precatalytic spliceosome (PubMed:[11350945](#), PubMed:[26912367](#)). Specifically regulates immunoglobulin gene rearrangement in a spliceosome-dependent manner, which involves modulating chromatin interactions at the Igh locus and therefore plays an essential role in B-cell development (By similarity). Regulates AURKB mRNA levels, and thereby plays a role in cytokinesis and in the spindle checkpoint (PubMed:[18728397](#)). Regulates apoptosis and G2/M cell cycle checkpoint in response to DNA damage by deubiquitinating and stabilizing CHK2 (PubMed:[30771428](#)). Also plays an important role in DNA repair by controlling the recruitment of XRCC4/LIG4 to DNA double-strand breaks for non-homologous end-joining repair (PubMed:[34614178](#)). Participates in antiviral activity by affecting the type I IFN signaling by stabilizing STAT1 and decreasing its 'Lys-6'-linked ubiquitination (PubMed:[33127822](#)). Contributes to non-canonical Wnt signaling during epidermal differentiation (By similarity). Acts as a negative regulator NF-kappa-B activation through deubiquitination of 'Lys-48'-linked ubiquitination of NFKBIA (PubMed:[36651806](#)).

#### **Cellular Location**


Nucleus

#### **USP39 Antibody (Center) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

#### **USP39 Antibody (Center) - Images**



USP39 Antibody (Center) (Cat. #AP18677c) western blot analysis in HeLa cell line lysates (35ug/lane). This demonstrates the USP39 antibody detected the USP39 protein (arrow).

#### **USP39 Antibody (Center) - Background**

USP39 may play a role in mRNA splicing. It is unsure if the protein really exhibits hydrolase activity. Could be a competitor of ubiquitin C-terminal hydrolases (UCHs).

#### **USP39 Antibody (Center) - References**

Rose, J. Phd, et al. Mol. Med. (2010) In press :  
van Leuken, R.J., et al. Cell Cycle 7(17):2710-2719(2008)  
Sugiyama, N., et al. Mol. Cell Proteomics 6(6):1103-1109(2007)  
Ewing, R.M., et al. Mol. Syst. Biol. 3, 89 (2007) :  
Olsen, J.V., et al. Cell 127(3):635-648(2006)